While I won't disagree with the advice posted so far, I will highlight that the only guidance on this topic is that "broadcast" DTC ads are covered under the PhRMA DTC Guidelines that members have committed to submitting for FDA Advisory Review. FDA has not come out and made any kind of determination that all of these new "channels" that are "like" broadcast, but not under that old school definition. FDA certainly welcomes and encourages pre-submission, but there is no requirement to do so in this case.
My experience has been that the decision to submit for FDA Advisory review (in the non-PhRMA covered scenario) is one that varies greatly across industry. I believe you can definitely and safely NOT submit and be fine, but if so you should be sure you have designed the content just like broadcast ad recommendations. That decision to submit for review is based on many factors: company risk tolerance, project timelines and budget, impact that potential comments from FDA will have on your entire promotional campaign as they will expect you to pull through comments across all of your promotional materials, etc.
Glenn Byrd
------------------------------
Glenn Byrd, MBA
President, GByrd Ad-Promo Solutions, LLC
President, RAPS Board of Directors
United States
------------------------------
Original Message:
Sent: 18-Feb-2021 13:33
From: Anonymous Member
Subject: Advertising and Promotion
This message was posted by a user wishing to remain anonymous
I am interested in the latest thinking on ads intended for Connected TV (e.g. Hulu). Does anyone have feedback on whether it's distinct enough from broadcast TV to go without preclearance or would you recommend treating it like broadcast TV?